» Articles » PMID: 34172469

Treatment of Cystic Fibrosis Airway Cells with CFTR Modulators Reverses Aberrant Mucus Properties Hydration

Abstract

Question: Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction ( acidic airway surface liquid (ASL) pH, low bicarbonate (HCO ) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown.

Materials/methods: We characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties.

Results: Loss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO , normalised mucus recovery to modulator-treated cell levels.

Conclusion: These results indicate that airway dehydration, not acidic pH and/or low [HCO ], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement.

Citing Articles

Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy.

Milczewska J, Syunyaeva Z, Zabinska-Jaron A, Sands D, Thee S Eur Respir Rev. 2024; 33(174).

PMID: 39631927 PMC: 11615665. DOI: 10.1183/16000617.0068-2024.


Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats.

Keith J, Murphree-Terry M, Bollar G, Oden A, Doty I, Birket S Respir Res. 2024; 25(1):397.

PMID: 39497082 PMC: 11536857. DOI: 10.1186/s12931-024-03029-0.


The lysogenic filamentous bacteriophage phage Pf slows mucociliary transport.

Burgener E, Cai P, Kratochvil M, Rojas-Hernandez L, Joo N, Gupta A PNAS Nexus. 2024; 3(9):pgae390.

PMID: 39301510 PMC: 11412248. DOI: 10.1093/pnasnexus/pgae390.


Cystic fibrosis.

Mall M, Burgel P, Castellani C, Davies J, Salathe M, Taylor-Cousar J Nat Rev Dis Primers. 2024; 10(1):53.

PMID: 39117676 DOI: 10.1038/s41572-024-00538-6.


Reduced sialylation of airway mucin impairs mucus transport by altering the biophysical properties of mucin.

Harris E, McIntire H, Mazur M, Schulz-Hildebrandt H, Leung H, Tearney G Sci Rep. 2024; 14(1):16568.

PMID: 39019950 PMC: 11255327. DOI: 10.1038/s41598-024-66510-2.


References
1.
Hill D, Vasquez P, Mellnik J, McKinley S, Vose A, Mu F . A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease. PLoS One. 2014; 9(2):e87681. PMC: 3928107. DOI: 10.1371/journal.pone.0087681. View

2.
Widdicombe J, Wine J . Airway Gland Structure and Function. Physiol Rev. 2015; 95(4):1241-319. DOI: 10.1152/physrev.00039.2014. View

3.
Schultz A, Puvvadi R, Borisov S, Shaw N, Klimant I, Berry L . Airway surface liquid pH is not acidic in children with cystic fibrosis. Nat Commun. 2017; 8(1):1409. PMC: 5680186. DOI: 10.1038/s41467-017-00532-5. View

4.
Tang X, Ostedgaard L, Hoegger M, Moninger T, Karp P, McMenimen J . Acidic pH increases airway surface liquid viscosity in cystic fibrosis. J Clin Invest. 2016; 126(3):879-91. PMC: 4767348. DOI: 10.1172/JCI83922. View

5.
Verdugo P . Supramolecular dynamics of mucus. Cold Spring Harb Perspect Med. 2012; 2(11). PMC: 3543103. DOI: 10.1101/cshperspect.a009597. View